ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.9411T>G (p.Thr3137=) (rs1799968)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000494944 SCV000578020 benign Breast-ovarian cancer, familial 2 2017-06-29 reviewed by expert panel curation Synonymous substitution variant, with low bioinformatic likelihood to alter mRNA splicing (splicing prior 0.02; and frequency 0.0033 (Finnish), derived from ExAC (2014-12-17).
Ambry Genetics RCV000163082 SCV000213585 likely benign Hereditary cancer-predisposing syndrome 2014-11-20 criteria provided, single submitter clinical testing
Invitae RCV001082585 SCV000253060 benign Hereditary breast and ovarian cancer syndrome 2019-12-31 criteria provided, single submitter clinical testing
GeneDx RCV000436726 SCV000516027 likely benign not specified 2017-08-10 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Color RCV000163082 SCV000689194 likely benign Hereditary cancer-predisposing syndrome 2017-01-13 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000588721 SCV000695238 benign not provided 2016-05-18 criteria provided, single submitter clinical testing Variant summary: The BRCA2 c.9411T>G (p.Thr3137Thr) variant involves the alteration of a non-conserved nucleotide, resulting in a synonymous change. One in silico tool predicts a damaging outcome for this variant, and 4/5 Alamut algorithms predict no significant change to splicing. This variant was found in 63/121504 control chromosomes, predominantly observed in the ExAC European (Finnish) subpopulation at a frequency of 0.0033303 (22/6606). This frequency is about 4 times the estimated maximal expected allele frequency of a pathogenic BRCA2 variant (0.0007503), suggesting this is likely a benign polymorphism found primarily in the populations of European (Finnish) origin. This variant has also been detected mainly in Finnish cancer patients from the literature, but without evidence of causality. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely benign. Taken together, this variant is classified as benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.